Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have ...

Ocugen is aligning major clinical and regulatory milestones for its three retinal gene therapy programs into a tight 2026-27 window, with a pivotal Phase III readout expected in early 2027. The ...

Ocugen has synchronized pivotal clinical and regulatory milestones for its three retinal gene therapy programs into 2026 and early 2027, targeting retinitis pigmentosa, Stargardt disease, and ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, will be presenting the results ...

Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.

BIO Capital continues support as founding investor, having backed Ray Therapeutics since seed funding in 2021 through Series ...

In April 2026, Ocugen, Inc. reported full Phase 2 ArMaDa trial results for OCU410 in geographic atrophy secondary to dry age-related macular degeneration, showing a 46% reduction in macular lesion ...

Ray Therapeutics (RayTx), an industry-leading clinical-stage biopharmaceutical company pioneering differentiated vision restoration therapies for those living with severe retinal ...

To Ocugen CEO Shankar Musunuri, Ph.D., most gene therapy biotechs today lack vision. | Many gene therapy outfits focus on ...

In 1991, the U.S. experienced a significant shift in cancer death rates, as, for the first time, deaths began a steady ...

The geographic atrophy (GA) enlargement rate in one eye does not consistently predict the enlargement rate in the fellow eye, according to a study published online April 2 in JAMA Ophthalmology. Leon ...

In life, it’s important to savor every moment. Take Ken, a man from Reno who is living a full life at an age when most people would be long retired. Eleven years ago – at age 77 – he began working as ...